deltatrials
Completed PHASE3 NCT02465567

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)

Sponsor: Pearl Therapeutics, Inc.

Conditions COPD
Interventions BFF MDI 320/9.6 μg BGF MDI 160/14.4/9.6 μg BGF MDI 320/14.4/9.6 μg GFF MDI 14.4/9.6 μg
Updated 20 times since 2017 Last updated: Feb 1, 2021 Started: Jun 30, 2015 Primary completion: Jul 26, 2019 Completion: Jul 26, 2019

Listed as NCT02465567, this PHASE3 trial focuses on COPD and remains completed. Sponsored by Pearl Therapeutics, Inc., it has been updated 20 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

20 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Mar 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 15 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE3

  2. Jul 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Mar 2020 — Jul 2020 [monthly]

    Completed PHASE3

  4. Feb 2020 — Mar 2020 [monthly]

    Completed PHASE3

  5. Oct 2019 — Feb 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  6. Aug 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Aug 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  10. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  11. Oct 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  12. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  13. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  14. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pearl Therapeutics, Inc.
Data source: Pearl Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain, Abingdon, United States, Adelaide, Australia, Ajax, Canada, Alcobendas, Spain, Alicante, Spain, Almelo, Netherlands, Almere Stad, Netherlands, Altoona, United States, Alzira, Spain and 550 more location s